Analysts and Calls - JP Morgan Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Analysts and Calls - JP Morgan

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

To: tuck who started this subject	3/19/2003 6:13:08 PM
From: tuck	of 3

[Maged Shenouda - Versicor] The split is over two week follow-up results of antifungal therapy pitting VERS' against fluconazole. Thomas Dietz of Pacific Growth says that in the real world, therapy would be continued, and thus relapses resulting from cessation of treatment are irrelevant. I would tend to agree, as does Fulcrum (who reiterated). But JP Morgan's analyst Maged Shenouda, says the inferior follow-up data puts it a commercial disadvantage to Merck's Cancidas. Message 18713250 Message 18720424 Anyone want to take sides, or shall we wait a couple of years for time to tell? Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext